Wednesday 28 February 2024
Salisbury Foundation Trust

FOI_7477

Internal Reference Number: FOI_7477

Date Request Received: 10/10/2023 00:00:00

Date Request Replied To: 19/10/2023 00:00:00

This response was sent via: By Email

Request Summary: Migraine

Request Category: Researcher

 
Question Number 1:
We are seeking to understand the funding and delivery of Botox and anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality, Vyepti, Vydura & Aquipta) for migraine. Could you please answer the following:

• Does the trust commission/fund Botox treatment for migraine (Y/N)?

• Does the trust commission/fund anti-CGRP treatments for migraine (Y/N)?

• Does the trust actively provide Botox/anti-CGRP treatments for migraine as opposed to sending patients to another trust (Y/N)? In case the trust does not provide these treatments, please provide the name of the trust to which you refer migraine patients for these treatments?

• In case the trust actively provides Botox/anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.
 
Answer To Question 1:
We are seeking to understand the funding and delivery of Botox and anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality, Vyepti, Vydura & Aquipta) for migraine. Could you please answer the following:

• Does the trust commission/fund Botox treatment for migraine - No

• Does the trust commission/fund anti-CGRP treatments for migraine - No

• Does the trust actively provide Botox/anti-CGRP treatments for migraine as opposed to sending patients to another trust - No

In case the trust does not provide these treatments, please provide the name of the trust to which you refer migraine patients for these treatments?

These treatments are provided for patients in our catchment by the Neurology Service, Wessex Neurological Centre, University Hospital Southampton (UHS).

• In case the trust actively provides Botox/anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust -

Funded by usual commissioning arrangements by local ICBs.

 
Question Number 2:
How many patients have been treated with the following drugs in the past 4 months:

• Atogepant (Aquipta) – any disease

• Erenumab (Aimovig) - any disease

• Eptinezumab (Vyepti) – any disease

• Fremanezumab (Ajovy) - any disease

• Galcanezumab (Emgality) - any disease

• Rimegepant (Vydura) – any disease

• Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY
 
Answer To Question 2:
None for all – patients in our catchment may be receiving these treatments from UHS but no data held on this at SDH
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Person Centred & Safe

Professional

Responsive

Friendly

Progressive

Salisbury NHS Foundation Trust, Salisbury District Hospital, Odstock Road, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2024 Salisbury NHS Foundation Trust
Trust Values